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Abstract
Background—Telomeres protect chromosomal ends, shorten with cellular division, and signal
cellular senescence but unchecked telomere attrition can lead to telomere dysfunction,
upregulation of telomerase, and carcinogenesis. Shorter telomeres in peripheral blood leukocytes
(PBLs) have been associated with elevated cancer risk. Further, genetic variants in and around the
TERT gene have been implicated in carcinogenesis.
Methods—We measured relative telomere length (RTL) in PBLs of 911 cases and 948 controls
from the New England Case Control Study, a population-based study of ovarian cancer. In
addition, we assessed germline genetic variation in five telomere maintenance genes among 2112
cases and 2456 controls from the New England Case Control Study and the Nurses’ Health Study,
a prospective cohort study. Odds ratios and 95% confidence intervals were estimated using
logistic regression.
Results—Overall, we observed no differences in telomere length between cases and controls.
Compared to women with RTL in the longest tertile, women with RTL in the shortest tertile had
no increase in risk (OR=1.01, 95% CI: 0.80, 1.28). However, several SNPs in the TERT gene,
including RS2736122, RS4246742, RS4975605, RS10069690, RS2736100, RS2853676,
RS7726159, were significantly associated with ovarian cancer risk. We observed a significant
gene-level association between TERT and ovarian cancer risk (p=0.00008).
Conclusion—Our observations suggest genetic variation in the TERT gene may influence
ovarian cancer risk, but the association between average telomere length in PBLs and ovarian
cancer remains unclear.
Impact—The role of telomeres in ovarian carcinogenesis remains unsettled and warrants further
investigation.
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BACKGROUND
Telomeres are repeated DNA sequences that protect chromosomal ends, shorten with each
cellular division, and signal cellular senescence. However, inactivation of tumor suppressors
such as p53 allow cells to circumvent senescence and telomeres erode until a crisis point is
reached (1). At this stage, cells are characterized by chromosomal aberrations and the
majority undergo apoptosis. A rare cell may reactivate telomerase expression allowing the
cell to escape apoptosis, become immortalized (2). Shorter telomeres in peripheral blood
leukocytes have been associated with a variety of cancers, including ovarian cancer (3) (4,
5).
Telomerase activity has been identified in some normal ovarian and fallopian tube tissue and
is thought to contribute in a controlled manner to oogenesis and fertility (6, 7). Conversely,
telomerase is not detectable in premalignant lesions but is upregulated in 90-97% of ovarian
cancers, suggesting deregulation of telomerase is a step in ovarian carcinogenesis (6). Twin
studies suggest that the majority (40-80% heritability) of interindividual variation in
telomere length is genetic (8, 9). Telomere length and stability is maintained by several
proteins, including telomerase (encoded in part by the TERT gene), TRF1, TRF2, and POT1
that act directly on telomeres, as well as TRF2IP, TINF2, and TNKS that interact directly
with components of the telomere complex (10). In addition, the importance of genetic
variation in TERT to cancer susceptibility has emerged from recent genome wide
association studies (GWAS) and candidate gene studies (11-17). Here we report the results
of relative telomere length measurements in peripheral blood leukocytes of 911 ovarian
cancer cases and 948 controls and germline genetic analyses in five telomere maintenance
genes among 2112 ovarian cancer cases and 2456 controls.
METHODS
Study populations
New England Case-Control Study (NECC)—Data and specimens from the New
England-based case-control study of ovarian cancer come from three enrollment phases
(1992-1997, 1998-2003, 2003-2008). Briefly, 3957 women residing in eastern
Massachusetts or New Hampshire with a diagnosis of incident ovarian cancer were
identified through hospital tumor boards and statewide cancer registries over three study
phases. Women were not eligible to be a case in the study if they had died, moved, lived
outside the study area, had no phone, did not speak English, or had a non-ovarian primary
tumor after review. Of the 3083 eligible cases, 2203 (71% of the eligible cases, 2076
epithelial cases) agreed to participate. All pathology reports were reviewed by a study
pathologist for consistency. Controls were identified through a combination of random digit
dialing, drivers’ license lists, and town resident lists. In the first phase, 420 (72%) of the
eligible women identified through random digit dialing agreed to participate and 102 (51%)
of the eligible women identified through town resident lists agreed to participate. In the
second and third phases, 4366 potential controls were identified, 2940 were eligible, 1362
declined to participate by phone or by mail via an “opt-out” postcard, and 1578 (54%) were
enrolled. Potential controls were required to meet the same eligibility criteria as cases. In
addition, controls were required to have at least one ovary. Controls were frequency
matched to cases on age and state of residence. All study participants were interviewed at
the time of enrollment about known and suspected ovarian cancer risk factors and asked to
complete a food frequency questionnaire. Over 97% of the participants provided a blood
specimen. In 558 cases diagnosed at Brigham and Women’s Hospital or Massachusetts
General Hospital, we abstracted chemotherapy data from medical records. Of the 434 cases
with RTL and abstracted clinical data, 302 received chemotherapy. Of these 51 had blood
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drawn before her chemotherapy. For the remainder, the mean time between chemotherapy
and blood draw was 35 days with an interquartile range of 20 to 165 days.
Nurses’ Health Study (NHS)—The NHS cohort was established in 1976 among 121,700
U.S. female registered nurses, ages 30 to 55 years. Women completed an initial
questionnaire, were followed biennially by questionnaire to update exposure status and
disease diagnoses, and completed a food frequency questionnaire every four years. In
1989-90, 32,826 participants submitted a blood sample (18). Follow-up of the NHS blood
study cohort was 96% in 2006. Self-reported diagnoses and deaths reported by family
members or identified through the U.S. National Death Index or U.S. Postal Service were
followed up for confirmation. A gynecologic pathologist confirmed the diagnosis of all
cases through a record review (19). For this analysis, we included all epithelial cases who
submitted a blood sample prior to diagnosis or within 4 years after diagnosis (n=162). All
cases were diagnosed before June 1, 2006 and had no history of a prior cancer, other than
non-melanoma skin cancer. We randomly selected three controls per case from the study
participants with DNA available, no prior bilateral oophorectomy, and no history of cancer,
other than non-melanoma skin cancer, at the questionnaire cycle coinciding with diagnosis
of the case, matching on age, menopausal status, postmenopausal hormone use, and timing
of blood draw.
Telomere length measurements
Genomic DNA from 990 cases and 1021 controls in the NECC study were standardized and
concentrations were measured using PicoGreen quantification by 96-well spectrophotometer
(Molecular Devices, Sunnyvale, CA). We used quantitative PCR as described previously
(20, 21) to estimate the ratio (T/S) of telomeric DNA to that of a single gene (36B4) copy
number derived from peripheral blood leukocytes. Briefly, 5ng of buffy-coat derived
genomic DNA was dried down in a 384-well plate and resuspended in 10μL of either the
Telomere or 36B4 PCR reaction mixture for 2 hours at 4C. The telomere reaction mixture
consisted of 1x Qiagen Quantitect Sybr Green Master Mix, 2.5mM of DTT, 270nM of
Tel-1b primer (GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT), and 900nM
of Tel-2b primer (TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA). The
reaction proceeded for 1 cycle at 95C for 5 min, followed by 30 cycles of at 95C for 15 sec,
and 54C for 2 min. The 36B4 reaction consisted of 1x Qiagen Quantitect Sybr Green Master
Mix, 300nM of 36B4U primer (CAGCAAGTGGGAAGGTGTAATCC), and 500nM of
36B4D primer (CCCATTCTATCATCAACGGGTACAA). The 36B4 reaction proceeded
for 1 cycle at 95C for 5 min, followed by 30 cycles at 95C for 15 sec, and 58C for 1 min 10
sec. Each 384-well plate contained a 6-point standard curve from 0.6ng to 20ng using
pooled buffy-coat derived genomic DNA. By obtaining slopes within -3.33 +/− 0.15 for
each standard curve, we were able to achieve 94% PCR efficiency. The T/S ratio (-dCt) for
each sample was calculated by subtracting the average 36B4 Ct value from the average
telomere Ct value. The relative T/S ratio (-ddCt) was determined by subtracting the T/S ratio
value of the 5ng standard curve point from the T/S ratio of each unknown sample. Assays
were performed in triplicate. 926 cases and 961 controls were successfully assayed.
Telomere and single gene coefficients of variation (CV) for triplicates were 1.7 and 1.6,
respectively. Cases and controls were evenly distributed across plates. Each plate contained
its own unique set of eight quality control samples, generated by aliquotting four replicates
from two designated samples. The intraplate CV for T/S ratio of QC samples was 10%. Our
assay was validated using cancer cell lines (SAOS, CYS-SV, ATS-V1), which showed a
strong correlation between T/S ratio and telomere length determined by Southern blot with
correlations ranging from 0.82-0.99. Cell lines were kindly provided by the laboratory of Dr.
Nikhil Munshi of the Dana Farber Cancer Institute. The cell lines were obtained greater than
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6 months prior to the assay from ATCC and were authenticated by the repository using
standard cytogenetic, morphological, antigen expression, and DNA profiling criteria.
SNP selection and genotyping
We identified 53 tagging SNPs in seven genes involved in telomere maintenance (TERT,
POT1, TNKS, TRF1, TINF2, TRF2, and TRF2IP) using publicly available data from the
HapMap Phase II. SNPs in TINF2 and TRF2IP were excluded because they monomorphic
in whites and POT1 SNP rs6946757 was excluded because we were unable to design an
assay for this SNP, resulting in 39 SNPs genotyped on 1173 cases, 1200 controls from the
first two phases of the NECC study. In phase 3 NECC and NHS, we used an alternative
platform that only allows multiples of 16 SNPs, therefore, we limited our SNP set to the top
31 SNPs and added a promising candidate SNP from the TERT gene (rs7726159) (11).
DNA was extracted from buffy coat samples using QIAmp (Qiagen, Chatsworth, CA);
samples were amplified using Genomiphi (GE Healthcare, Piscataway, NJ). All genotyping
was performed at the DF/HCC High Throughput Polymorphism Core. First, we genotyped
39 SNPs on the first two phases of the NECC study using 5′ nuclease assays (Taqman®) on
the Applied Biosystems Prism 7900HT Sequence Detection System (Applied Biosystems,
Foster City, California). Then, we genotyped 32 SNPs on phase 3 NECC samples and the
NHS samples using the Applied Biosystems Taqman OpenArray genotyping platform.
Replicate samples (approximately 10%) included for quality control had 100% concordance.
Genotyping was performed by laboratory personnel blinded to case-control status and
quality control replicates. Over 95% of the samples were successfully genotyped for each
polymorphism.
Statistical analysis
Relative telomere length (RTL) analysis—RTL values were adjusted for 384-well
plate using batch adjustment methods described previously (22). Outliers were identified
using the extreme studentized deviate many-outlier procedure (23) and excluded from
further analysis (n=29). Tertiles were determined based on the distribution in controls.
Among controls, we tested for differences in the distribution of relative telomere length by
categories of epidemiologic characteristics using the Wilcoxon rank sum and Kruskal Wallis
tests as well as linear regression for multivariate adjusted analyses. Unconditional logistic
regression adjusted for the matching factors and study phase were used to calculate odds
ratios (OR) and 95% confidence intervals (95% CI) for the association between tertiles of
RTL and ovarian cancer risk. Multivariate models were additionally adjusted for oral
contraceptive use (<3 months, 3 months- 2 years, 2-5 years, >5 years), parity (0, 1, 2, 3, 4+),
tubal ligation, BMI (<21.9, 22-24.6, 25.7-28.3, >28.3), smoking (never, past, current),
family history of breast or ovarian cancer, and race (white, non-white).
Histology specific analyses were performed comparing RTL in a particular histologic group
to all controls. We evaluated the association between RTL and ovarian cancer risk within
subgroups of ovulatory cycles, genital talc use, smoking, and BMI. We performed tests for
interaction using a likelihood ratio test to compare models with and without the interaction
terms.
Among the subset of cases with telomere length measurements and date of last
chemotherapy before blood draw (n=256), we performed a sensitivity analysis to assess the
influence of recent chemotherapy on the association between RTL in PBLs and ovarian
cancer by excluding cases with blood drawn within 3 or 6 months of chemotherapy. Further,
we used polytomous logistic regression (24) to assess whether the association between RTL
and risk of serous invasive ovarian cancer differed by time between diagnosis and blood
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draw, as this may also reflect chemotherapy status. We calculated estimates for the
association between RTL and ovarian cancer risk for cases with blood draw within 283 days
of diagnosis (population median) versus more than 283 after diagnosis.
SNP analysis—There were no SNPs out of Hardy-Weinberg Equilibrium at p<0.001 in
any dataset. SNP associations were evaluated using a log-additive model where the odds
ratio represents the incremental increase or decrease in risk with each additional allele.
Unconditional logistic regression adjusted for the matching factors (age and study center)
was used for the NECC analyses and conditional logistic regression was used in the NHS
analysis. We restricted to whites because we observed that several SNP frequencies varied
by race. Multivariate models were additionally adjusted for oral contraceptive use, parity,
tubal ligation, and family history of breast or ovarian cancer. Estimates from NECC phases
1&2, NECC phase 3, and NHS were combined by meta-analysis using fixed effects models
to calculate summary odds ratios and 95% confidence intervals. We used PACT to account
for multiple testing in correlated tests (25). Variables evaluated for effect modification
included those associated with ovarian cancer and/or thought to influence telomere length,
including estimated lifetime number of ovulatory cycles, talc use, BMI, exercise, dietary
folate, and total folate (which includes vitamins and supplements).
To evaluate gene level associations, we employed a principal components approach
described previously by Gauderman and colleagues that accounts for linkage disequilibrium
between SNPs (26). Briefly, we estimated the combinations of SNPs, grouped as principal
components (PCs) that represent the genetic variation across the gene. Then, we included the
fewest number of PCs that together describe at least 80% of the variation in a logistic
regression with ovarian cancer as the outcome. Using a likelihood ratio test, we compared
models with and without selected principal components to determine the association
between the gene of interest and ovarian cancer risk. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC) or Intercooled Stata 9.2 (StataCorp, College
Station, TX).
RESULTS
Population characteristics for the first two phases of the NECC study and the NHS nested
case control study have been reported previously (27). Participants in NECC phase 3 were
similar to those in the previous two phases. However, phase 3 participants were slightly
older, more likely to have taken oral contraceptives, and cases were more likely to be
invasive. Among controls with telomere length measurements (Table 1), RTL was inversely
associated with age (r = −0.21, p<0.0001) and BMI (r = −0.12, p=0.0002). BMI remained
independently, although modestly, associated with RTL after adjustment for age (r = −0.08,
p=0.02). Former smokers had significantly shorter telomeres on average than women who
never smoked (age-adjusted p=0.04), but there were no differences between current and
never smokers. Oral contraceptive use, parity, tubal ligation, family history of breast or
ovarian cancer, estimated lifetime number of ovulatory cycles, and Jewish ancestry were not
associated with telomere length.
Overall, we observed no significant difference in mean RTL between 911 women with
epithelial ovarian cancer (mean = 0.75, standard deviation (std) = 0.40) versus 948 controls
(mean = 0.77, std = 0.51). Compared to women with telomeres in the longest tertile of
length, those with telomeres in the shortest tertile of length had no increased risk of ovarian
cancer overall (OR=1.01, 95% CI: 0.80, 1.28) or serous invasive cancer (OR= 1.11, 95% CI:
0.82, 1.51) (Table 2). Associations did not significantly differ between high-grade
(OR=1.09, 95% CI: 0.80, 1.50) and low-grade (OR=0.88, 95% CI: 0.30-2.64) serous
invasive ovarian cancer. Results were similar for other histologic subtypes and when
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considering quartile or quintile cutpoints. Evaluating the RTL-ovarian cancer association
within subgroups did not reveal any interactions with ovulatory cycles, genital talc use,
endometriosis, or smoking. However, the association between RTL and ovarian cancer
differed significantly by quartiles of BMI (p-heterogeneity=0.01). Among overweight
women (BMI > 28.3), women with the shortest telomeres had a borderline decreased risk
compared to women with the longest telomeres (OR=0.62, 95% CI: 0.38, 1.01), but among
women with a BMI less than 21.9 (OR=1.29, 95% CI: 0.79, 2.10) and women with a BMI
between 22 and 24.6 (OR=1.06, 95% CI: 0.67, 1.66) shorter telomeres were not associated
with ovarian cancer risk.
The association between RTL and risk of serous invasive ovarian cancer did not differ
significantly between cases with blood drawn less than or equal to median time between
diagnosis and blood draw (OR=0.89, 95% CI: 0.67, 1.18) compared to those with blood
drawn longer after diagnosis (OR=1.21, 95% CI: 0.90, 1.62, pheterogeneity = 0.13). Although
non-significant, the association between RTL and ovarian cancer risk tended to increase as
cases who had recently had chemotherapy were excluded from the analyses. For example,
odds ratios for ovarian cancer, comparing shortest to longest tertiles of relative telomere
length, were 1.20 (95% CI: 0.66-2.19) when restricting to cases with blood drawn more than
3 months after chemotherapy (n=82) and 1.51 (95% CI: 0.67, 3.40) when restricting to cases
with blood drawn more than 6 months after chemotherapy (n=53).
We genotyped 40 tagging SNPs in five telomere maintenance genes (TERT, TRF2, TRF1,
TNKS, and POT1) in the NECC and NHS studies. Minor allele frequencies were similar
across all three datasets. Overall, we observed seven significant associations for TERT
SNPs, but no significant associations for other SNPs. TERT SNPs rs4246742, rs4975605,
rs10069690, rs2736100, rs2853676 and rs7726159 were associated with 11-19% increase in
ovarian cancer risk with each additional variant allele, while rs2736122 was associated with
an 11% decrease in risk with each allele (Table 3), but none of these associations remained
significant after permutation testing. On a gene level, estimated principal components
accounting for 88% of the genetic variation in TERT were significantly associated with
ovarian cancer (p=0.00008), but principal components of other genes were not associated
with risk.
Interestingly, histology-specific associations revealed that TERT SNPs rs4246742 (pooled
OR=1.43, 95% CI: 1.12, 1.83), rs4975605 (pooled OR=1.26, 95%CI: 1.05, 1.51), and
rs10069690 (pooled OR=1.28, 95% CI: 1.04, 1.57) were most strongly associated with
endometrioid tumors, while rs2853676 was more strongly associated with serous invasive
ovarian cancer (OR=1.14, 95%CI: 1.00, 1.30). RS2736100 was associated with a significant
increase in borderline tumors (pooled OR=1.24, 95% CI: 1.05, 1.46). In stratified analyses,
we evaluated the association between telomere maintenance SNPs and ovarian cancer risk
by estimated lifetime number of ovulatory cycles, BMI, exercise, genital talc use, folate
intake, and smoking; however, we did not observe any significant interactions after
adjustment for multiple testing.
Among 918 white controls from the NECC study, we evaluated the association between
SNPs in telomere maintenance genes and RTL in peripheral blood leukocytes. We observed
significant age-adjusted differences in telomere length by genotype for POT1 SNPs
rs929365 (p=0.02) and rs4360236 (p=0.04), but these SNPs were not associated with
ovarian cancer risk.
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DISCUSSION
Our data shows an association between genetic variation in the TERT gene and ovarian
cancer risk in three datasets with significant associations between six individual TERT SNPs
and ovarian cancer risk and a highly significant gene level association with risk. In our
telomere length analysis, we observed shorter telomeres in peripheral blood leukocytes with
increasing age, former smoking, and higher BMI as previously reported in the literature (28,
29) but no significant association between RTL in peripheral blood leukocytes and ovarian
cancer risk in the largest study of telomere length and ovarian cancer risk to date.
When considered independently, the magnitude of the association between any individual
TERT SNP we genotyped and ovarian cancer risk was small and of borderline significance,
and a combined analysis of four ovarian cancer GWAS studies showed no significant
associations between these individual TERT SNPs and overall ovarian cancer risk
(unpublished data). However, when we considered the TERT variants together in a principal
components analysis that accounts for linkage disequilibrium between the SNPs, we
observed a highly significant association (p=0.00008), suggesting that these individual SNPs
do not capture the importance of genetic variation in this region. In the context of other
recent reports of significant associations between TERT SNPs and risk of various cancers,
including ovarian cancer (11-17), our data suggest that genetic variation in the TERT gene
may be important to ovarian cancer susceptibility. In a study of 1,309 SNPs in 173 genes
involved in stromal epithelial cross-talk, Johnatty and colleagues observed that TERT
rs7726159 was significantly associated with serous invasive ovarian cancer (ORper-allele =
1.14, 95% CI=1.04-1.24) and an inverse association of borderline significance between
rs2736100 and serous ovarian cancer (OR=0.88, 95% CI=0.77-1.01) (11). Furthermore,
rs2736100 has emerged from recent GWAS studies as a potential susceptibility allele for
glioma (OR=1.27, p=2 × 10−17) (15), lung cancer (OR=1.14, p=4×10−6) (12), and testicular
cancer (OR=1.33, p=8×10−15) (17). Based on this accumulating evidence, the area around
the TERT gene has been hypothesized to be cancer polymorphism “hot-spot” that may
influence many types of cancer (11, 13, 14).
Given the emerging evidence that p53 mutations are likely precursors to most serous ovarian
cancers (37) and p53 mutations are also observed in endometrioid ovarian tumors (38), the
telomere maintenance pathway may have particular relevance to these tumors. Interestingly,
Kuhn and colleagues found that telomeres measured in tissue from serous tubal
intraepithelial carcinoma (STIC) were significantly shorter than those found in concurrent
high grade serous ovarian carcinoma and suggested that the shortened telomeres STICs
represents an early carcinogenic event while longer telomeres in coexisting high grade
serous tumors are a result of subsequent activation of telomerase and immortalization (39).
Although none of the TERT SNPs we found to be associated with ovarian cancer was
associated with telomere length in peripheral blood leukocytes of controls, the influence of
these SNPs on other telomere attributes cannot be ruled out. Telomere attrition can occur
due to a range of insults that increase cellular turnover, accelerate telomeric DNA damage,
or result in defective telomere repair. Therefore, the influence of a single SNP on telomere
length may be difficult to detect. Furthermore, these SNPs may influence carcinogenesis
through a pathway that does not involve telomere length. For instance, Artandi and
colleagues have shown that TERT interacts directly with WNT transcription factors and
cooperate in activating WNT responsive promoters while Mancke and colleagues have
recently shown telomerase interacts with β-catenin (reviewed in (40)). Interestingly, WNT
and β-catenin have been implicated in ovarian carcinogenesis (41).
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Our telomere length and ovarian cancer risk results contrast those of two small case-control
studies that previously reported significantly increased ovarian cancer risk with shorter
telomeres (4, 5). Idei and colleagues observed shorter mean telomere lengths in DNA from
plasma from 32 cases (≥ stage 3) versus controls in a Japanese population. In addition, long-
term (≥10 years) ovarian cancer survivors had significantly longer telomeres than other
cases, suggesting a survival benefit with increased telomere length (4). Similarly, Mirabello
and colleagues reported shorter leukocyte telomere length in 99 serous ovarian cancer cases
compared to 100 controls in a Polish population, with a 3-fold increase in risk for women
with telomere length in the shortest tertile (OR=3.39, 95% CI: 1.54-7.46) (5). Differences in
study populations, study design, sample size, timing of chemotherapy, and type of specimen
or assay may explain inconsistencies between our own results and previous studies.
Telomere length has been shown to vary by ethnicity (30), which vary between these
studies. Furthermore, telomere length in DNA obtained from plasma (4) may differ from
that derived from buffy coat, and cases in the Polish study were recruited sooner after
diagnosis (median 2.4 months) than in our study (median 9.3 months), such that time since
chemotherapy likely differed between the studies.
Several studies have suggested that chemotherapy may influence measureable telomere
length in peripheral blood leukocytes, but conclusions are mixed showing both increases and
decreases in length as well as changes in telomerase activity after chemotherapy (4, 31-34).
In prospectively collected serial samples, one study reported that telomere length post-
chemotherapy was approximately 550 base pairs shorter than pre-chemotherapy (34) while
another reported significant telomere shortening in peripheral blood mononuclear cells after
multiple cycles of chemotherapy (33). Cisplatin, a standard therapy for ovarian cancer,
forms DNA adducts with telomeric sequences and results in telomere loss in cell lines (31).
In our study, telomere lengths were shorter on average as time since chemotherapy
increased, suggesting an influence of chemotherapy. Thus, the association between RTL and
ovarian cancer risk may be obscured in samples collected after treatment. Yet, Mirabello and
colleagues observed no difference in telomere length between samples collected before
(telomere length=0.89, 95% CI: 0.89-0.99) and after chemotherapy (telomere length=0.91,
95% CI: 0.82-0.99). Regardless, telomere length measurements in post-diagnostic samples
can be difficult to interpret because samples collected soon after diagnosis are likely to be
influenced by chemotherapy or active disease and those collected later are likely influenced
by survival (35).
Given the well documented inverse correlation between BMI and relative telomere length
noted in our study and by others (28, 29), our subgroup analyses showing a reduced risk of
ovarian cancer for women in the highest quartile of weight is counterintuitive as one would
expect the highest cancer risk for obese women with short telomeres. These results are likely
a chance finding due to a limited distribution of telomere length in this subgroup.
A limitation of our study is the use of telomere length in PBLs as a surrogate for telomere
length in the ovaries or fallopian tubes. A range of exposures including chronic infection or
other immune insults could accelerate cellular turnover in white blood cells leading to
shorter telomeres compared to tissue. However, telomere length in a variety of tissues are
highly synchronous (42), and matched blood and tissue samples correlated (4, 43). Although
this is a large study with over 2112 cases and 2456 controls in the SNP analysis and 911
cases in 948 controls in the telomere length analysis, power is limited to detect significant
associations within subgroups of histologic types, particularly rarer subtypes.
Our findings regarding genetic variation in the TERT gene and ovarian cancer risk add to
the growing body of literature suggesting the importance of this genetic region to cancer
development. Further research is needed in this area to understand how changes in telomere
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length over time may influence ovarian carcinogenesis in a prospective setting and
interaction with a p53 pathway of development.
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Table 3
Association between SNPs in telomere-related genes and risk of ovarian cancer in NECC (1992-2008) and
NHS (1976-2006)*
Gene rs number OR† Per allele95% CI pgene∥
TERT RS2736122 0.89 (0.81, 0.99) 0.00008
TERT RS2075786 1.06 (0.97, 1.17)
TERT RS4246742 1.19 (1.05, 1.35)
TERT RS6882077‡ 1.31 (0.27, 6.29)
TERT RS4975605 1.11 (1.02, 1.22)
TERT RS10069690 1.11 (1.00, 1.23)
TERT RS2242652‡ 1.06 (0.91, 1.24)
TERT RS2736100 1.12 (1.02, 1.23)
TERT RS2853676 1.13 (1.02, 1.25)
TERT RS2736098 0.99 (0.89, 1.09)
TERT RS7726159‡ 1.17 (1.02, 1.34)
TRF2 RS251796 0.94 (0.85, 1.04) 0.59
TRF2 RS153045 0.94 (0.86, 1.04)
TRF2 RS3785074 1.06 (0.96, 1.18)
TRF2 RS166134‡ 0.79 (0.48, 1.28)
TRF2 RS8061382‡ 1.07 (0.74, 1.55)
TRF1 RS2975842 1.01 (0.93, 1.11) 0.99
TRF1 RS2975852 1.03 (0.94, 1.14)
TRF1 RS6989159‡ 0.95 (0.40, 2.25)
TRF1 RS6989493‡ 1.19 (0.44, 3.26)
TRF1 RS12334686 1.02 (0.93, 1.12)
TRF1 RS6982126 0.97 (0.87, 1.08)
TRF1 RS2981096‡ 0.94 (0.69, 1.26)
TRF1 RS10107605 1.00 (0.87, 1.15)
TRF1 RS1545827 1.01 (0.93, 1.10)
TNKS RS1539041 0.98 (0.89, 1.08) 0.34
TNKS RS3802650 1.02 (0.94, 1.12)
TNKS RS10509637 1.01 (0.89, 1.15)
TNKS RS1772180 0.93 (0.85, 1.02)
TNKS RS10509639 1.11 (0.94, 1.30)
TNKS RS1772186 0.98 (0.86, 1.11)
TNKS RS10881982‡ 1.03 (0.72, 1.49)
TNKS RS12412538 1.07 (0.97, 1.18)
TNKS RS7087365 1.06 (0.96, 1.17)
POT1 RS929365 0.96 (0.79, 1.18) 0.79
POT1 RS7801661 1.02 (0.92, 1.13)
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Gene rs number OR† Per allele95% CI pgene∥
POT1 RS11972248 0.96 (0.86, 1.07)
POT1 RS12532038 1.01 (0.91, 1.11)
POT1 RS4360236 1.14 (0.99, 1.32)
POT1 RS2896361 0.98 (0.90, 1.08)
*
Restricted to white women.
†Adjusted for age (continuous), center, oral contraceptive use (never, 1-24, 25-72, >72 months), parity (0, 1, 2+), family history of breast or
ovarian cancer, and tubal ligation. The combined analysis is additionally adjusted for genotyping batch.
§
Meta-analysis of NECC phases 1&2, NECC phase 3, and NHS using fixed effects model. We observed significant heterogeneity between datasets
for TRF1 SNP RS12334686 (pheterogeneity = 0.04) and TNKS SNP RS1772180 (pheterogeneity = 0.02).
‡
RS6882077, RS2242652, RS166134, RS8061382, RS6989159, RS6989493, RS2981096, RS10881982 were not genotyped in NECC phase 3 and
NHS datasets and RS7726159 was not genotyped in NECC phases 1 and 2.
∥
Principal components analyses were used to determine gene-level associations with ovarian cancer risk accounting for linkage disequilibrium
between SNPs
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